合成目标产物 Anacetrapib 主要起始原料 2-Oxazolidinone, 5-[3,5-Bis(Trifluoromethyl)Phenyl]-4-Methyl-, (4S,5R)- And 4'-Fluoro-2'-Methoxy-5'-Isopropyl-4-Trifluoromethyl-1,1'-Biphenyl-2-Methanol
875550-10-0 = 875446-37-0 [标题:Reaction Conditions 标题:N,C-Disubstituted Biarylpalladacycles As Precatalysts For Ppm Pd-Catalyzed Cross Couplings In Water Under Mild Conditions 作者:Thakore,Ruchita R.; Et Al 参考文献:Acs Catalysis 日期:2019 卷标:9(12) 页码:11647-11657]
958029-47-5 = 875446-37-0 [标题:Reaction Conditions 标题:Arene Ruthenium Catalyst Mcat-53 For The Synthesis Of Heterobiaryl Compounds In Water Through Aromatic C-H Bond Activation 作者:Mehta,Anita; Et Al 参考文献:Organic Process Research & Development 日期:2018 卷标:22(9) 页码:1119-1130]
875446-29-0 + 875446-35-8 = 875446-37-0 反应条件:1.1 Reagents: Sodium Carbonate Catalysts: Tetrakis(Triphenylphosphine)Palladium Solvents: Ethanol,Benzene,Water; 14 H,100 °C 标题:Biphenyl-Substituted Oxazolidinones As Cholesteryl Ester Transfer Protein Inhibitors: Modifications Of The Oxazolidinone Ring Leading To The Discovery Of Anacetrapib 作者:Smith,Cameron J.; Et Al 参考文献:Journal Of Medicinal Chemistry 日期:2011 卷标:54(13) 页码:4880-4895
专利号:WO-2013091696-A1 优先权日:2011-12-21 标题 :Synthesis of intermediates for preparing anacetrapib and derivatives thereof 发明人:HUMLJAN JAN; MARAS NENAD 权利人:LEK PHARMACEUTICALS; HUMLJAN JAN; MARAS NENAD 摘要:The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.
专利号:EP-2468735-A1 优先权日:2010-12-23 标 题:Synthesis of intermediates for preparing anacetrapib and derivates thereof 权利人:LEK PHARMACEUTICALS 摘要:The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.
专利号:US-9212118-B2 优先权日:2010-12-23 标题:Synthesis of intermediates for preparing anacetrapib and derivatives thereof 发明人:HUMLJAN JAN; MARAS NENAD 权利人:HUMLJAN JAN; MARAS NENAD; LEK PHARMACEUTICALS 摘要:The present invention relates to the field of organic chemistry, more specifically to the synthesis of intermediate compounds which can be used in the synthesis of pharmaceutically active agents such as anacetrapib or derivatives thereof.
专利号:US-10005720-B2 优先权日:2013-04-05 标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same 发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L 权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL 摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.
专利号:US-10865163-B2 优先权日:2017-12-20 标题:Carbon dioxide as a directing group for C—H functionalization reactions involving Lewis basic amines, alcohols, thiols, and phosphines for the synthesis of compounds 发明人:YOUNG MICHAEL C; KAPOOR MOHIT 权利人:UNIV TOLEDO 摘要:Methods of synthesizing compounds using CO 2 as a directing group for C—H functionalization, and compounds made thereby, are described.
专利号:US-10300471-B2 优先权日:2013-10-08 标题 :Ruthenium-catalyzed synthesis of biaryl compounds in water 发明人:KOOHANG ALI AIDEN; MEHTA ANITA 权利人:CHICAGO DISCOVERY SOLUTIONS LLC 摘要:Using a [RuCl 2 (arene)] 2 complex and a formate source, a directed ortho C—H insertion and aryl-aryl coupling sequence in water provides biaryl compounds useful in the preparation of biologically active molecules and intermediates. Reactions may be conducted in the ambient atmosphere. Ruthenium catalysts prepared from [RuCl 2 (arene)] 2 and a formate source may be prepared in situ or isolated for later use.
1: Krishna R, Stypinski D, Ali M, Garg A, Cote J, Maes A, Degroot B, Liu Y, Li S, Connolly SM, Wagner JA, Stoch SA. Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2012 Jul;74(1):116-24. doi: 10.1111/j.1365-2125.2012.04171.x. Epub 2011 Dec 22. Epub 2011 Dec 17. 4: Gutstein DE, Krishna R, Johns D, Surks HK, Dansky HM, Shah S, Mitchel YB, Arena J, Wagner JA. Anacetrapib, a novel CETP inhibitor: pursuing a new approach to cardiovascular risk reduction. Clin Pharmacol Ther. 2012 Jan;91(1):109-22. doi: 10.1038/clpt.2011.271. Epub 2011 Nov 30. Review. Review. doi: 10.1002/bdd.776. Epub 2011 Sep 1. Epub 2011 Aug 14. 9: Smith CJ, Ali A, Hammond ML, Li H, Lu Z, Napolitano J, Taylor GE, Thompson CF, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Sparrow CP, Wright SD, Cumiskey AM, Latham M, Peterson LB, Rosa R, Pivnichny JV, Tong X, Xu SS, Sinclair PJ. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib. J Med Chem. 2011 Jul 14;54(13):4880-95. Epub 2011 Jun 17. Erratum in: Curr Opin Lipidol. 2011 Aug;22(4):326.
合成参考文献
摘要:Seki, M., Science of Synthesis: Catalytic Transformations via CH Activation, (2015) 1, 148. 摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198 参考文献:10.1517/13543784.17.4.445 摘要:Athyros VG, Kakafika A, Tziomalos K, Karagiannis A, Mikhailidis DP. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended Expert Opinion on Investigational Drugs. 2008 Mar 25;17(4):445–9. doi: 10.1517/13543784.17.4.445. 参考文献:10.1097/mol.0b013e3283475e00 摘要:Niesor EJ. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism. Curr Opin Lipidol. 2011 Aug;22(4):288–95. doi: 10.1097/mol.0b013e3283475e00. 参考文献:10.1007/s11883-012-0290-8 摘要:Hochholzer W, Giugliano RP. Does it make sense to combine statins with other lipid-altering agents following AIM-HIGH, SHARP and ACCORD Curr Atheroscler Rep. 2013 Jan;15(1):290. doi: 10.1007/s11883-012-0290-8.